440 related articles for article (PubMed ID: 25865214)
1. Allogeneic stem cell transplantation in multiple myeloma: immunotherapy and new drugs.
Festuccia M; Martino M; Ferrando F; Messina G; Moscato T; Fedele R; Boccadoro M; Giaccone L; Bruno B
Expert Opin Biol Ther; 2015 Jun; 15(6):857-72. PubMed ID: 25865214
[TBL] [Abstract][Full Text] [Related]
2. Allogeneic hematopoietic stem cell transplantation for multiple myeloma: curative but not the standard of care.
Koehne G; Giralt S
Curr Opin Oncol; 2012 Nov; 24(6):720-6. PubMed ID: 22960558
[TBL] [Abstract][Full Text] [Related]
3. Treatment of multiple myeloma.
San Miguel JF; Bladé Creixenti J; García-Sanz R
Haematologica; 1999 Jan; 84(1):36-58. PubMed ID: 10091392
[TBL] [Abstract][Full Text] [Related]
4. Outcome of allogeneic transplantation in newly diagnosed and relapsed/refractory multiple myeloma: long-term follow-up in a single institution.
Franssen LE; Raymakers RA; Buijs A; Schmitz MF; van Dorp S; Mutis T; Lokhorst HM; van de Donk NW
Eur J Haematol; 2016 Nov; 97(5):479-488. PubMed ID: 27028304
[TBL] [Abstract][Full Text] [Related]
5. Allogeneic stem cell transplantation in multiple myeloma relapsed after autograft: a multicenter retrospective study based on donor availability.
Patriarca F; Einsele H; Spina F; Bruno B; Isola M; Nozzoli C; Nozza A; Sperotto A; Morabito F; Stuhler G; Festuccia M; Bosi A; Fanin R; Corradini P
Biol Blood Marrow Transplant; 2012 Apr; 18(4):617-26. PubMed ID: 21820394
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcome after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with multiple myeloma.
El-Cheikh J; Crocchiolo R; Furst S; Stoppa AM; Ladaique P; Faucher C; Calmels B; Lemarie C; De Colella JM; Granata A; Coso D; Bouabdallah R; Chabannon C; Blaise D
Am J Hematol; 2013 May; 88(5):370-4. PubMed ID: 23460414
[TBL] [Abstract][Full Text] [Related]
7. Monoclonal antibody therapy in multiple myeloma: where do we stand and where are we going?
Thanendrarajan S; Davies FE; Morgan GJ; Schinke C; Mathur P; Heuck CJ; Zangari M; Epstein J; Yaccoby S; Weinhold N; Barlogie B; van Rhee F
Immunotherapy; 2016; 8(3):367-84. PubMed ID: 26888183
[TBL] [Abstract][Full Text] [Related]
8. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
Talmadge JE
Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic stem cell transplantation for multiple myeloma: is there a future?
Dhakal B; Vesole DH; Hari PN
Bone Marrow Transplant; 2016 Apr; 51(4):492-500. PubMed ID: 26726943
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy for multiple myeloma: Current status and future directions.
Ayed AO; Chang LJ; Moreb JS
Crit Rev Oncol Hematol; 2015 Dec; 96(3):399-412. PubMed ID: 26153389
[TBL] [Abstract][Full Text] [Related]
11. Establishment of a murine graft-versus-myeloma model using allogeneic stem cell transplantation.
Binsfeld M; Beguin Y; Belle L; Otjacques E; Hannon M; Briquet A; Heusschen R; Drion P; Zilberberg J; Bogen B; Baron F; Caers J
PLoS One; 2014; 9(11):e113764. PubMed ID: 25415267
[TBL] [Abstract][Full Text] [Related]
12. Beyond consolidation: auto-SCT and immunotherapy for plasma cell myeloma.
Lendvai N; Cohen AD; Cho HJ
Bone Marrow Transplant; 2015 Jun; 50(6):770-80. PubMed ID: 25751647
[TBL] [Abstract][Full Text] [Related]
13. Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma.
Podar K; Jager D
Curr Cancer Drug Targets; 2017; 17(9):782-805. PubMed ID: 28201977
[TBL] [Abstract][Full Text] [Related]
14. [Graft-versus-host disease associated with lenalidomide maintenance after allogeneic transplantation for relapsed/refractory multiple myeloma].
Tsukada N; Shingaki S; Ikeda M; Miyazaki K; Meshitsuka S; Yoshiki Y; Abe Y; Suzuki K
Rinsho Ketsueki; 2015 Jul; 56(7):895-900. PubMed ID: 26256927
[TBL] [Abstract][Full Text] [Related]
15. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
Chung C
Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
[TBL] [Abstract][Full Text] [Related]
16. The role of positron emission tomography with 18F-fluorodeoxyglucose integrated with computed tomography in the evaluation of patients with multiple myeloma undergoing allogeneic stem cell transplantation.
Patriarca F; Carobolante F; Zamagni E; Montefusco V; Bruno B; Englaro E; Nanni C; Geatti O; Isola M; Sperotto A; Buttignol S; Stocchi R; Corradini P; Cavo M; Fanin R
Biol Blood Marrow Transplant; 2015 Jun; 21(6):1068-73. PubMed ID: 25754658
[TBL] [Abstract][Full Text] [Related]
17. Partially T-cell-depleted allogeneic stem-cell transplantation for first-line treatment of multiple myeloma: a prospective evaluation of patients treated in the phase III study HOVON 24 MM.
Lokhorst HM; Segeren CM; Verdonck LF; van der Holt B; Raymakers R; van Oers MH; Barge RM; Schouten HC; Westveer PH; Steijaert MM; Cornelissen JJ; Sonneveld P;
J Clin Oncol; 2003 May; 21(9):1728-33. PubMed ID: 12721248
[TBL] [Abstract][Full Text] [Related]
18. In search of the optimal platform for Post-Allogeneic SCT immunotherapy in relapsed multiple myeloma: a systematic review.
Oostvogels R; Uniken Venema SM; de Witte M; Raymakers R; Kuball J; Kröger N; Minnema MC
Bone Marrow Transplant; 2017 Sep; 52(9):1233-1240. PubMed ID: 28692028
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy for Multiple Myeloma, Past, Present, and Future: Monoclonal Antibodies, Vaccines, and Cellular Therapies.
Karp Leaf R; Cho HJ; Avigan D
Curr Hematol Malig Rep; 2015 Dec; 10(4):395-404. PubMed ID: 26338470
[TBL] [Abstract][Full Text] [Related]
20. Cellular immunotherapy as a therapeutic approach in multiple myeloma.
Liegel J; Avigan D; Rosenblatt J
Expert Rev Hematol; 2018 Jul; 11(7):525-536. PubMed ID: 29856648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
